PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (...
January 18 2018 - 1:10AM
YASTEST
REGULATED INFORMATION
GHENT, Belgium,
18 January 2018 - Ablynx [Euronext Brussels
and Nasdaq: ABLX] today announced, in accordance with Article
14 of the Belgian Law of 2 May 2007 regarding the publication of
major shareholdings in issuers whose securities are admitted to
trading on a regulated market (the "Transparency Law"), that it
received a notification of shareholdings from FMR LLC on 16 and 17
January 2018.
FMR LLC (taking into account the
holdings of its subsidiary undertakings) now holds a total of
7,230,164 voting securities of Ablynx, representing 9.68% of the
current 74,720,644 outstanding voting rights of Ablynx (versus
9.50% notified previously on 25 August 2017).
FMR LLC has notified Ablynx that
FMR Co., Inc., a subsidiary of Fidelity Management & Research
Company, which itself is a subsidiary of FMR LLC (the ultimate
parent company) has downward crossed the 5% threshold of voting
rights of Ablynx since 15 January 2018 and upward crossed the 3%
threshold of voting rights held through financial instruments since
16 January 2018.
The notification contains the
following information:
-
Reason for the
notification:
-
Notification by: a parent
undertaking or a controlling person
-
Persons subject to the
notification requirement: FMR LLC
-
Transaction date: 15 and 16
January 2018
-
Threshold that is crossed:
5% of voting rights and 3% of voting rights held through financial
instruments
-
Denominator:
74,720,644
-
Details of the
notification:
Name of select subsidiaries
of
FMR LLC |
% of voting rights |
% of voting rights held through financial
instruments* |
Total of both |
FMR LLC
Fidelity Management & Research Company
FMR Co., Inc. |
4.41% |
3.21% |
7.62% |
FMR LLC
FIAM Holdings Corp.
Fidelity Institutional Asset Management Trust Company |
1.05% |
|
1.05% |
FMR LLC
FIAM Holdings Corp.
FIAM LLC |
1.02% |
|
1.02% |
TOTAL |
6.47% |
3.21% |
9.68% |
* Type of
financial instrument: "Right of Recall
-
Chain of controlled
undertakings through which the holding is effectively being
held: The holdings attributable to FMR LLC arise from holdings
of various undertakings for collective investment that are managed
by FMR Co., Inc., Fidelity Institutional Asset Management Trust
Company and FIAM LLC, each of which are entities that are
subsidiaries of, and controlled by, FMR LLC. These undertakings for
collective investment have granted FMR LLC discretionary power to
vote the securities in accordance with the FMR LLC board proxy
voting policy. FMR LLC is not a controlled undertaking.
More information is available in
the transparency notification. Full versions of both transparency
notifications are available on Ablynx website, under the section
Investors.
The articles of the association of
Ablynx NV provide for shareholders notification threshold of 3%, 5%
or a multiple of 5% of the total number of existing voting
rights.
About
Ablynx
Ablynx is a biopharmaceutical
company engaged in the development of Nanobodies®, proprietary
therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with
some of the features of small-molecule drugs. Ablynx is dedicated
to creating new medicines which will make a real difference to
society. Today, the Company has more than 45 proprietary and
partnered programmes in development in various therapeutic areas
including inflammation, haematology, immuno-oncology, oncology and
respiratory disease. The Company has collaborations with multiple
pharmaceutical companies including AbbVie; Boehringer Ingelheim;
Eddingpharm; Merck & Co., Inc., Kenilworth, New Jersey, USA;
Merck KGaA; Novartis; Novo Nordisk; Sanofi and Taisho
Pharmaceuticals. The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
For more
information, please contact
Ablynx:
Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com
Lies Vanneste
Director Investor Relations
t: +32 (0)9 262 01 37
m: +32 (0)498 05 35 79
e: lies.vanneste@ablynx.com
Follow us on Twitter @AblynxABLX
Ablynx media
relations:
Consilium Strategic Communications
Mary-Jane Elliott, Philippa Gardner, Sukaina Virji
t: +44 (0)20 3709 5700
e: ablynx@consilium-comms.com
pdf version of the press
release
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Ablynx via Globenewswire
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ablynx NV (NASDAQ:ABLX)
Historical Stock Chart
From Apr 2023 to Apr 2024